Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Growth Factor Receptor—Thyroxine Kinase Inhibitors

This publication has 30 references indexed in Scilit:

• Tumor Heterogeneity and Personalized Medicine
  New England Journal of Medicine, 2012
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  The Lancet Oncology, 2011
• Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas
  Journal of Clinical Oncology, 2011
• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
  Clinical Cancer Research, 2011
• Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
  Nature, 2009
• Dynamic Proteomics of Individual Cancer Cells in Response to a Drug
  Science, 2008
• Circulating mutant DNA to assess tumor dynamics
  Nature Medicine, 2008
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  PLOS Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• The STATs of cancer — new molecular targets come of age
  Nature Reviews Cancer, 2004